Bioresorbable vascular scaffolds-basic concepts and clinical outcome

Nature Reviews Cardiology

Volumn 13, Issue 12, 2016, Pages 719-729

  Indolfi, Ciro ^a,b   De Rosa, Salvatore ^a   Colombo, Antonio ^c,d  

^a UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^b CNR   (Italy)

^c SAN RAFFAELE HOSPITAL   (Italy)

^d EMO GVM CENTRO CUORE COLUMBUS   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BIORESORBABLE VASCULAR STENT; CLINICAL TRIAL (TOPIC); CORONARY ARTERY OBSTRUCTION; DUAL ANTIPLATELET THERAPY; HUMAN; IMPLANTATION; IN-STENT RESTENOSIS; META ANALYSIS (TOPIC); MULTICENTER STUDY (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; STENT THROMBOSIS; SYSTEMATIC REVIEW (TOPIC); TREATMENT DURATION; BIODEGRADABLE IMPLANT; BLOOD VESSEL TRANSPLANTATION; DEVICES; POSTOPERATIVE COMPLICATION; PROCEDURES; PROSTHESIS DESIGN; RECURRENT DISEASE; STENT; THROMBOSIS;

ABSORBABLE IMPLANTS; BLOOD VESSEL PROSTHESIS IMPLANTATION; CORONARY STENOSIS; HUMANS; POSTOPERATIVE COMPLICATIONS; PROSTHESIS DESIGN; RECURRENCE; STENTS; THROMBOSIS;

EID: 84989271308     PISSN: 17595002     EISSN: 17595010     Source Type: Journal    
DOI: 10.1038/nrcardio.2016.151     Document Type: Review

References (89)

1. Indolfi, C., Pavia, M., & Angelillo, I. F. Drug-eluting stents versus bare metal stents in percutaneous coronary interventions (a meta-analysis). Am. J. Cardiol. 95, 1146-1152 (2005
2. Holmes, D. R., et al. Thrombosis and drug-eluting stents: an objective appraisal. J. Am. Coll. Cardiol. 50, 109-118 (2007
3. Gareri, C., de Rosa, S., & Indolfi, C. MicroRNAs for restenosis and thrombosis after vascular injury. Circ. Res. 118, 1170-1184 (2016
4. Byrne, R. A., et al. Report of a European Society of Cardiology-European Association of Percutaneous Cardiovascular Interventions task force on the evaluation of coronary stents in Europe: executive summary. Eur. Heart J. 36, 2608-2620 (2015
5. Ormiston, J. A., & Serruys, P. W. Bioabsorbable coronary stents. Circ. Cardiovasc. Interv. 2, 255-260 (2009
6. Serruys, P. W., et al. Dynamics of vessel wall changes following the implantation of the Absorb everolimus eluting bioresorbable vascular scaffold: a multi-imaging modality study at 6, 12, 24 and 36 months. EuroIntervention 9, 1271-1284 (2014
7. Serruys, P. W., et al. Evaluation of the second generation of a bioresorbable everolimus drug-eluting vascular scaffold for treatment of de novo coronary artery stenosis: six-month clinical and imaging outcomes. Circulation 122, 2301-2312 (2010
8. Zhang, Y. J., et al. Comparison of acute gain and late lumen loss after PCI with bioresorbable vascular scaffolds versus everolimus-eluting stents: an exploratory observational study prior to a randomised trial. EuroIntervention. 10, 672-680 (2014
9. Tanimoto, S., et al. Comparison of in vivo acute stent recoil between the bioabsorbable everolimus-eluting coronary stent and the everolimuseluting cobalt chromiumcoronary stent: insights fromthe ABSORB and SPIRIT trials. Catheter Cardiovasc. Interv. 70, 515-523 (2007
10. Gomez-Lara, J., et al. A comparison of the conformability of everolimus-eluting bioresorbable vascular scaffolds to metal platform coronary stents. JACC Cardiovasc. Interv. 3, 1190-1198 (2010
11. Ferdous, J., Kolachalama, V. B., Kolandaivelu, K., & Shazly, T. Degree of bioresorbable vascular scaffold expansion modulates loss of essential function. Acta Biomater. 26, 195-204 (2015
12. Indolfi, C., et al. Neointimal proliferation is associated with clinical restenosis 2 years after fully bioresorbable vascular scaffold implantation. Circ. Cardiovasc. Imaging 7, 755-757 (2014
13. Ishida, K., Giacchi, G., Brugaletta, S., Garcia-Alvarez, A., & Sabate, M. Unfavorable bioresorbable vascular scaffold resorption, a cause of restenosis? Cardiovasc. Revasc. Med. http://dx.doi.org/10.1016/j.carrev.2016.05.013 (2016
14. Serruys, P. W., et al. A bioabsorbable everolimus-eluting coronary stent system (ABSORB): 2 year outcomes and results from multiple imaging methods. Lancet 373, 897-910 (2009
15. Sarno, G., et al. Morphological and functional evaluation of the bioresorption of the bioresorbable everolimus-eluting vascular scaffold using IVUS, echogenicity and vasomotion testing at two year follow up: a patient level insight into the ABSORB A clinical trial. Int. J. Cardiovasc. Imaging 28, 51-58 (2012
16. Ormiston, J. A., et al. First serial assessment at 6 months and 2 years of the second generation of absorb everolimus-eluting bioresorbable vascular scaffold: a multi-imaging modality study. Circ. Cardiovasc. Interv. 5, 620-632 (2012
17. Serruys, P. W., et al. Evaluation of the second generation of a bioresorbable everolimus-eluting vascular scaffold for the treatment of de novo coronary artery stenosis 12 month clinical and imaging outcomes. J. Am. Coll. Cardiol. 58, 1578-1588 (2011
18. Brugaletta, S., et al. Endothelial-dependent vasomotion in a coronary segment treated by ABSORB everolimus-eluting bioresorbable vascular scaffold system is related to plaque composition at the time of bioresorption of the polymer: indirect finding of vascular reparative therapy? Eur. Heart J. 33, 1325-1333 (2012
19. Togni, M., et al. Sirolimus-eluting stents associated with paradoxic coronary vasoconstriction. J. Am. Coll. Cardiol. 46, 231-236 (2005
20. Hofma, S. H., et al. Indication of long-term endothelial dysfunction after sirolimus-eluting stent implantation. Eur. Heart J. 27, 166-170 (2006
21. Simsek, C., et al. Long-term invasive follow up of the everolimus-eluting bioresorbable vascular scaffold: five-year results of multiple invasive imaging modalities. EuroIntervention 11, 996-1003 (2016
22. Haude, M., et al. Safety and performance of the second-generation drug-eluting absorbable metal scaffold in patients with de novo coronary artery lesions (BIOSOLVE II): 6 month results of a prospective, multicentre, non-randomized, first in man trial. Lancet 387, 31-39 (2016
23. Puricel, S., et al. Bioresorbable coronary scaffold thrombosis: multicenter comprehensive analysis of clinical presentation, mechanisms, and predictors. J. Am. Coll. Cardiol. 67, 921-931 (2016
24. Costopoulos, C., et al. Comparison of early clinical outcomes between Absorb bioresorbable vascular scaffold and everolimus-eluting stent implantation in a real-world population. Catheter Cardiovasc. Interv. 85, E10-E15 (2015
25. Mattesini, A., et al. ABSORB biodegradable stents versus second-generation metal stents: a comparison study of 100 complex lesions treated under OCT guidance. JACC Cardiovasc. Interv. 7, 741-750 (2014
26. Robaei, D., Back, L., Ooi, S. Y., Pitney, M., & Jepson, N. Twelve-month outcomes with bioresorbable everolimus-eluting scaffold: results of the ESHC-BVS Registry at two Australian centers. J. Invasive Cardiol. 28, 316-322 (2016
27. Ishibashi, Y., et al. Relation between bioresorbable scaffold sizing using QCA-Dmax and clinical outcomes at 1 year in 1,232 patients from 3 study cohorts (ABSORB Cohort B, ABSORB EXTEND, and ABSORB II). JACC Cardiovasc. Interv. 8, 1715-1726 (2015
28. Miyazaki, T., et al. The use of a scoring balloon for optimal lesion preparation prior to bioresorbable scaffold implantation: a comparison with conventional balloon predilatation. EuroIntervention 11, e1580-e1588 (2016
29. Heusch, G., et al. a-Adrenergic coronary vasoconstriction and myocardial ischemia in humans. Circulation 101, 689-694 (2000
30. Indolfi, C., et al. Role of alpha 2 adrenoceptors in normal and atherosclerotic human coronary circulation. Circulation 86, 1116-1124 (1992
31. Kawamoto, H., Jabbour, R. J., Tanaka, A., Latib, A., & Colombo, A. The bioresorbable scaffold: will oversizing affect outcomes? JACC Cardiovasc. Interv. 9, 299-300 (2016
32. Colombo, A., & Ruparelia, N. Who is thrombogenic: the scaffold or the doctor? Back to the future JACC Cardiovasc. Interv. 9, 25-27 (2016
33. Souteyrand, G., et al. Mechanisms of stent thrombosis analysed by optical coherence tomography: insights from the national PESTO French registry. Eur. Heart J. 37, 1208-1216 (2016
34. Sorrentino, S., et al. The duration of balloon inflation affects the luminal diameter of coronary segments after bioresorbable vascular scaffolds deployment. BMC Cardiovasc. Disord. 15, 169 (2015
35. Biscaglia, S., et al. Bioresorbable scaffold versus second generation drug eluting stent in long coronary lesions requiring overlap: a propensity-matched comparison (the UNDERDOGS study). Int. J. Cardiol. 208, 40-45 (2016
36. Kawamoto, H., Ruparelia, N., Tanaka, A., Latib, A., & Colombo, A. Minimal acute recoil following bioresorbable scaffold implantation in fibrocalcific lesion detected by optical frequency-domain imaging. J. Invasive Cardiol. 28, E34-E36 (2016
37. Caiazzo, G., et al. Optical coherence tomography guidance for percutaneous coronary intervention with bioresorbable scaffolds. Int. J. Cardiol. 221, 352-358 (2016
38. Tamai, H., et al. Initial 6 month results of biodegradable poly l lactic acid coronary stents in humans. Circulation 102, 399-404 (2000
39. Nishio, S., et al. Long-term (>10 years) clinical outcomes of first in humans biodegradable poly l lactic acid coronary stents Igaki-Tamai stents. Circulation 125, 2343-2352 (2012
40. Serruys, P. W., et al. Bioresorbable everolimus-eluting scaffold versus a metallic everolimus-eluting stent for ischaemic heart disease caused by de novo native coronary artery lesions (ABSORB II): an interim 1 year analysis of clinical and procedural secondary outcomes from a randomised controlled trial. Lancet 385, 43-54 (2012
41. Gao, R., et al. Bioresorbable vascular scaffolds versus metallic stents in patients with coronary artery disease: ABSORB China trial. J. Am. Coll. Cardiol. 66, 2298-2309 (2015
42. Ellis, S. G., et al. Everolimus-eluting bioresorbable scaffolds for coronary artery disease. N. Engl. J. Med. 373, 1905-1915 (2015
43. Kimura, T., et al. A randomized trial evaluating everolimus-eluting Absorb bioresorbable scaffolds versus everolimus-eluting metallic stents in patients with coronary artery disease: ABSORB Japan. Eur. Heart J. 36, 3332-3342 (2015
44. Puricel, S., et al. Comparison of everolimus-and biolimus-eluting coronary stents with everolimus-eluting bioresorbable vascular scaffolds. J. Am. Coll. Cardiol. 65, 791-801 (2015
45. Sabat?, M. Everolimus-eluting bioresorbable stent versus durable polymer everolimus-eluting metallic stent in patients with ST segment elevation myocardial infarction: results of the randomized ABSORB ST segment elevation myocardial infarction-TROFI II trial. Eur. Heart J. 37, 229-240 (2016
46. Caiazzo, G., et al. Absorb bioresorbable vascular scaffold: what have we learned after 5 years of clinical experience? Int. J. Cardiol. 201, 129-136 (2015
47. Capodanno, D., et al. Percutaneous coronary intervention with everolimus-eluting bioresorbable vascular scaffolds in routine clinical practice: early and midterm outcomes from the European multicentre GHOST EU registry. EuroIntervention 10, 1144-1153 (2015
48. Kraak, R. P., et al. Initial experience and clinical evaluation of the Absorb bioresorbable vascular scaffold (BVS) in real-world practice: the AMC Single Centre Real World PCI registry. EuroIntervention 10, 1160-1168 (2015
49. Wfhrle, J., et al. Beyond the early stages: insights from the ASSURE registry on bioresorbable vascular scaffolds. EuroIntervention 11, 149-156 (2015
50. Hoppmann, P., et al. Angiographic and clinical outcomes of patients treated with everolimus-eluting bioresorbable stents in routine clinical practice: Results of the ISAR-ABSORB registry. Catheter Cardiovasc. Interv. 87, 822-829 (2016
51. Abizaid, A., et al. The ABSORB EXTEND study: preliminary report of the twelve-month clinical outcomes in the first 512 patients enrolled. EuroIntervention 10, 1396-1401 (2015
52. Rzeszutko, Ł., et al. Contemporary use of bioresorbable vascular scaffolds (BVS) in patients with stable angina and acute coronary syndromes. Polish National Registry. Kardiol. Pol. 72, 1394-1399 (2014
53. Felix, C. M., et al. Mid-to long-term clinical outcomes of patients treated with the everolimus-eluting bioresorbable vascular scaffold: The BVS Expand Registry. JACC Cardiovasc. Interv. 9, 1652-1663 (2016
54. Dudek, D., et al. Bioresorbable vascular scaffolds in patients with acute coronary syndromes: the POLAR ACS study. Pol. Arch. Med. Wewn. 124, 669-677 (2014
55. Gori, T., et al. Early outcome after implantation of Absorb bioresorbable drug-eluting scaffolds in patients with acute coronary syndromes. EuroIntervention 9, 1036-1041 (2014
56. Wiebe, J., et al. Short-term outcome of patients with ST segment elevation myocardial infarction (STEMI) treated with an everolimus-eluting bioresorbable vascular scaffold. Clin. Res. Cardiol. 103, 141-148 (2014
57. Kajiya, T., et al. Everolimus-eluting bioresorbable vascular scaffold (BVS) implantation in patients with ST segment elevation myocardial infarction (STEMI). EuroIntervention 9, 501-504 (2013
58. Kočka, V., et al. Bioresorbable vascular scaffolds in acute ST segment elevation myocardial infarction: a prospective multicentre study 'Prague 19'. Eur. Heart J. 35, 787-794 (2014
59. Diletti, R., et al. Everolimus-eluting bioresorbable vascular scaffolds for treatment of patients presenting with ST segment elevation myocardial infarction: BVS STEMI first study. Eur. Heart J. 35, 777-786 (2014
60. Cortese, B., et al. Clinical comparison with short-term follow up of bioresorbable vascular scaffold versus everolimus-eluting stent in primary percutaneous coronary interventions. Am. J. Cardiol. 116, 705-710 (2015
61. Brugaletta, S., et al. Absorb bioresorbable vascular scaffold versus everolimus-eluting metallic stent in ST segment elevation myocardial infarction: 1 year results of a propensity score matching comparison: the BVS-EXAMINATION study (bioresorbable vascular scaffold a clinical evaluation of everolimus eluting coronary stents in the treatment of patients with ST segment elevation myocardial infarction). JACC Cardiovasc. Interv. 8, 189-197 (2015
62. Goktekin, O., et al. Evaluation of the safety of everolimus-eluting bioresorbable vascular scaffold (BVS) implantation in patients with chronic total coronary occlusions: acute procedural and short-term clinical results. J. Invasive Cardiol. 27, 461-466 (2015
63. Moscarella, E., et al. Long-term clinical outcomes after bioresorbable vascular scaffold implantation for the treatment of coronary in stent restenosis: a multicenter italian experience. Circ. Cardiovasc. Interv. 9, e003148 (2016
64. Gil, R. J., et al. The use of bioresorbable vascular scaffold Absorb BVS® in patients with stable coronary artery disease: one-year results with special focus on the hybrid BVS and DES treatment. Kardiol Pol. 74, 627-633 (2016
65. de Ribamar Costa, J., et al. Initial results of the FANTOM 1 trial: a first in man evaluation of a novel, radiopaque sirolimus-eluting bioresorbable vascular scaffold. J. Am. Coll. Cardiol. 67, 232-232 (2016
66. Abizaid, A. Reva Fantom: differentiating features and studies. Presented at: Joint Interventional Meeting, 11-13 Feb 2016, Milan, Italy
67. Erbel, R., et al. Temporary scaffolding of coronary arteries with bioabsorbable magnesium stents: a prospective, non-randomised multicentre trial. Lancet 369, 1869-1875 (2007
68. Haude, M., et al. Safety and performance of the drug eluting absorbable metal scaffold (DREAMS) in patients with de novo coronary lesions: 12 month results of the prospective, multicentre, first-in man BIOSOLVE I trial. Lancet 381, 836-844 (2013
69. Bouchi, Y. H., & Gogas, B. D. Biocorrodible metals for coronary revascularization: lessons from PROGRESS-AMS, BIOSOLVE I, and BIOSOLVE II. Glob. Cardiol. Sci. Pract. 2015, 63 (2015
70. Waksman, R. The disappearing stent: when plastic replaces metal. Circulation 125, 2291-2294 (2012
71. Indolfi, C., et al. Smooth muscle cell proliferation is proportional to the degree of balloon injury in a rat model of angioplasty. Circulation 92, 1230-1235 (1995
72. Lipinski, M. J., Escarcega, R. O., Lhermusier, T., & Waksman, R. The effects of novel, bioresorbable scaffolds on coronary vascular pathophysiology. J. Cardiovasc. Transl Res. 7, 413-425 (2014
73. Onuma, Y., et al. Intra-coronary optical coherence tomography and histology at 1 month and 2, 3, and 4 years after implantation of everolimus-eluting bioresorbable vascular scaffolds in a porcine coronary artery model: an attempt to decipher the human optical coherence tomography images in the ABSORB trial. Circulation 122, 2288-2300 (2010
74. Lipinski, M. J., et al. Scaffold thrombosis after percutaneous coronary intervention with ABSORB bioresorbable vascular scaffold a systematic review and meta-analysis. JACC Cardiovasc. Interv. 9, 12-24 (2016
75. Çiçek, G., Açikgoz, S. K., Yayla, Ç., Kundi, H., & Íleri, M. Magnesium as a predictor of acute stent thrombosis in patients with ST segment elevation myocardial infarction who underwent primary angioplasty. Coron. Artery Dis. 27, 47-51 (2016
76. Fokkema, M. L., et al. Outcome after percutaneous coronary intervention for different indications: long-term results from the Swedish Coronary Angiography and Angioplasty Registry (SCAAR). EuroIntervention 12, 303-311 (2016
77. Petronio, A. S. 30 day results of the Italian diffuse/multivessel disease ABSORB prospective registry (IT DISAPPEARS). Presented at: EuroPCR 2016, 17 May 2016, Paris, France
78. Cortese, B. 30 day outcome of the Italian ABSORB registry (RAI), a prospective registry of consecutive patients treated with biovascular scaffold. Presented at: EuroPCR 2016, 17 May 2016, Paris, France
79. Koning, R. France ABSORB registry: in hospital and one-month results in 2,000 patients. Presented at: EuroPCR 2016, 17 May 2016, Paris, France
80. Serruys, P. W., et al. A polylactide bioresorbable scaffold eluting everolimus for treatment of coronary stenosis: 5 year follow up. J. Am. Coll. Cardiol. 67, 766-776 (2016
81. Yahagi, K., Virmani, R., & Kesavamoorthy, B. Very late scaffold thrombosis of everolimus-eluting bioresorbable scaffold following implantation in STEMI after discontinuation of dual antiplatelet therapy. Cardiovasc. Interv Ther. 31 Oct 2015 [epub ahead of print
82. Silber, S., et al. Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation. Eur. Heart J. 35, 1949-1956 (2014
83. Van Geuns, R. J. Effect of DAPT termination at 12 months on very late scaffold thrombosis in regular clinical practice: data on a regional collaboration including 868 patients. Presented at: EuroPCR 2016, 17 May 2016, Paris, France
84. Carino, A., et al. Modulation of circulating microRNAs levels during the switch from clopidogrel to ticagrelor. Biomed. Res. Int. 2016, 3968206 (2016
85. Caiazzo, G., et al. Administration of a loading dose has no additive effect on platelet aggregation during the switch from ongoing clopidogrel treatment to ticagrelor in patients with acute coronary syndrome. Circ. Cardiovasc. Interv. 7, 104-112 (2014
86. Franchi, F., & Angiolillo, D. J. Novel antiplatelet agents in acute coronary syndrome. Nat. Rev. Cardiol. 12, 30-47 (2015
87. Tateishi, H., et al. Edge vascular response after resorption of the everolimus-eluting bioresorbable vascular scaffold- a 5 year serial optical coherence tomography study. Circ. J. 80, 1131-1141 (2016
88. Dalos, D., et al. Mechanical properties of the everolimus-eluting bioresorbable vascular scaffold compared to the metallic everolimus-eluting stent. BMC Cardiovasc. Disord. 16, 104 (2016
89. de Rosa, S., & Indolfi, C. Letter by de Rosa and Indolfi regarding article, "Clinical presentation and outcomes of coronary in-stent restenosis across 3-stent generations". Circ. Cardiovasc. Interv. 8, e002375 (2015